These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 37032379)

  • 1. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
    Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
    Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.
    Xu-Monette ZY; Wei L; Fang X; Au Q; Nunns H; Nagy M; Tzankov A; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Sun X; Han X; Go H; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Albitar M; You H; Young KH
    Clin Cancer Res; 2022 Mar; 28(5):972-983. PubMed ID: 34980601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.
    Frauenfeld L; Castrejon-de-Anta N; Ramis-Zaldivar JE; Streich S; Salmerón-Villalobos J; Otto F; Mayer AK; Steinhilber J; Pinyol M; Mankel B; Ramsower C; Bonzheim I; Fend F; Rimsza LM; Salaverria I; Campo E; Balagué O; Quintanilla-Martinez L
    Blood Adv; 2022 Apr; 6(7):2361-2372. PubMed ID: 34654055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
    Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM
    N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary bone diffuse large B-cell lymphoma (PB-DLBCL): a distinct extranodal lymphoma of germinal centre origin, with a common EZB-like mutational profile and good prognosis.
    Ivanova VS; Davies J; Menter T; Wild D; Müller A; Krasniqi F; Stenner F; Papachristofilou A; Dirnhofer S; Tzankov A
    Histopathology; 2024 Feb; 84(3):525-538. PubMed ID: 37965677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
    Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
    BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.
    Zhu Y; Fu D; Shi Q; Shi Z; Dong L; Yi H; Liu Z; Feng Y; Liu Q; Fang H; Cheng S; Wang L; Tian Q; Xu P; Zhao W
    Front Immunol; 2022; 13():842439. PubMed ID: 35401516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
    Pedrosa L; Fernández-Miranda I; Pérez-Callejo D; Quero C; Rodríguez M; Martín-Acosta P; Gómez S; González-Rincón J; Santos A; Tarin C; García JF; García-Arroyo FR; Rueda A; Camacho FI; García-Cosío M; Heredero A; Llanos M; Mollejo M; Piris-Villaespesa M; Gómez-Codina J; Yanguas-Casás N; Sánchez A; Piris MA; Provencio M; Sánchez-Beato M
    Sci Rep; 2021 Jan; 11(1):1886. PubMed ID: 33479306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16.
    Wang P; Xu L; Fan Y; Li B; Chen P; Zhang X; Sun Y; Fu J
    Leuk Lymphoma; 2022 Dec; 63(14):3370-3377. PubMed ID: 36239491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
    Hu S; Xu-Monette ZY; Tzankov A; Green T; Wu L; Balasubramanyam A; Liu WM; Visco C; Li Y; Miranda RN; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Slack GW; Gascoyne RD; Tu M; Variakojis D; Chen W; Go RS; Piris MA; Møller MB; Medeiros LJ; Young KH
    Blood; 2013 May; 121(20):4021-31; quiz 4250. PubMed ID: 23449635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
    Ok CY; Xu-Monette ZY; Li L; Manyam GC; Montes-Moreno S; Tzankov A; Visco C; Dybkær K; Routbort MJ; Zhang L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Rao H; Møller MB; Winter JN; Piris MA; Wang SA; Medeiros LJ; Young KH
    Mod Pathol; 2015 Sep; 28(9):1202-13. PubMed ID: 26111978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-grade B-cell lymphoma with
    Scott DW; King RL; Staiger AM; Ben-Neriah S; Jiang A; Horn H; Mottok A; Farinha P; Slack GW; Ennishi D; Schmitz N; Pfreundschuh M; Nowakowski GS; Kahl BS; Connors JM; Gascoyne RD; Ott G; Macon WR; Rosenwald A
    Blood; 2018 May; 131(18):2060-2064. PubMed ID: 29475959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Characterization and Genetic Subclassification Comparison of Diffuse Large B-Cell Lymphoma: Real-Life Experience with 74 Cases.
    Ivanova VS; Vela V; Dirnhofer S; Dobbie M; Stenner F; Knoblich J; Tzankov A; Menter T
    Pathobiology; 2024; 91(4):245-253. PubMed ID: 38128501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement.
    Carreras J; Ikoma H; Kikuti YY; Miyaoka M; Hiraiwa S; Tomita S; Kondo Y; Ito A; Nagase S; Miura H; Kawada H; Roncador G; Campo E; Hamoudi R; Nakamura N
    Virchows Arch; 2024 Apr; 484(4):657-676. PubMed ID: 38462571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.
    Meriranta L; Pasanen A; Alkodsi A; Haukka J; Karjalainen-Lindsberg ML; Leppä S
    Blood Adv; 2020 Aug; 4(15):3742-3753. PubMed ID: 32780847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.
    Morichika K; Karube K; Sakihama S; Watanabe R; Kawaki M; Nishi Y; Nakachi S; Okamoto S; Takahara T; Satou A; Shimada S; Shimada K; Tsuzuki T; Fukushima T; Morishima S; Masuzaki H
    Am J Surg Pathol; 2021 Jun; 45(6):832-840. PubMed ID: 33899787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.